Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sichuan Biokin Pharmaceutical Co's FCF Margin % or its related term are showing as below:
SHSE:688506'
s FCF Margin % Range Over the Past 10 Years
Min: -124.1 Med: -3.87 Max: 68.26
Current: -62.62
During the past 12 years, the highest FCF Margin % of Sichuan Biokin Pharmaceutical Co was 68.26%. The lowest was -124.10%. And the median was -3.87%.
SHSE:688506's FCF Margin % is ranked worse than 89.74% of 965
companies
in the Drug Manufacturers industry
Industry Median: 2.73
vs SHSE:688506: -62.62
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Biokin Pharmaceutical Co FCF Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Sichuan Biokin Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sichuan Biokin Pharmaceutical Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sichuan Biokin Pharmaceutical Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sichuan Biokin Pharmaceutical Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sichuan Biokin Pharmaceutical Co (SHSE:688506) has a FCF Margin % of -1,007.01% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sichuan Biokin Pharmaceutical Co and its competitors. According to the industry distribution chart, Sichuan Biokin Pharmaceutical Co ranks #866 out of 965 companies in the Drug Manufacturers industry, placing it in the top 89.7%.
Is Sichuan Biokin Pharmaceutical Co's FCF Margin % too high?
Sichuan Biokin Pharmaceutical Co's current FCF Margin % is -1,007.01%. Based on the distribution chart, Sichuan Biokin Pharmaceutical Co ranks #866 out of 965 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sichuan Biokin Pharmaceutical Co has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sichuan Biokin Pharmaceutical Co's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sichuan Biokin Pharmaceutical Co ranks #866 out of 965 companies for FCF Margin %. This places Sichuan Biokin Pharmaceutical Co in the lower half of its industry. The industry median FCF Margin % is 2.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.73, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sichuan Biokin Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sichuan Biokin Pharmaceutical Co's current FCF Margin % is -1,007.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sichuan Biokin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sichuan Biokin Pharmaceutical Co (SHSE:688506) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥287.73, compared to a current price of ¥238.62 — trading 17.1% below its estimated fair value. The current FCF Margin % is -1,007.01%. Sichuan Biokin Pharmaceutical Co's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sichuan Biokin Pharmaceutical Co (SHSE:688506), the current FCF Margin % is -1,007.01% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sichuan Biokin Pharmaceutical Co (SHSE:688506) Overvalued in 2026?
Based on GuruFocus' analysis, Sichuan Biokin Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥238.62 is trading 17.1% below its estimated GF Value™ of ¥287.73.
GuruFocus considers Sichuan Biokin Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:688506:
FCF Margin %: -1,007.01%
GF Value™: ¥287.73 vs. price of ¥238.62 (17.1% below fair value)
No single metric tells the full story. See the SHSE:688506 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sichuan Biokin Pharmaceutical Co Ltd is a chemical drug and biological drug-based company that integrates drug research and development, production and marketing.
79GF Score
Get the complete analysis for SHSE:688506
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688506 has been successfully added to your 
